Sanofi's once-daily diabetes drug Lyxumia approved in Europe
4 February 2013
Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"
23 November 2012
Sanofi buys Colombian drugmaker; Presents encouraging eliglustat and Lyxumia data; Revizes deal with B-MS
3 October 2012
Highlights of American Diabetes Association meeting
11 June 2012
$20 million lixisenatide milestone for Zealand Pharma
13 February 2012
Sanofi files for EU approval of Lyxumia, a type-2 diabetes agent partnered with Zealand Pharma
4 November 2011
Sanofi presents positive results with Lyxumia and Lantus in type 2 diabetes at EASD meeting
13 September 2011
Most surveyed physicians in Europe expect to increase Rxing of GLP-1 analogues and DPP-IV inhibitors
18 August 2011
Showing 1-12 of 12 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
